BridgeMD
Examination of the molecular profile in adolescent patients with histiocytic cell hyperplasia, and if a specific mutation is detected, its monitoring. Determination clinical benefit of use fludeoxyglucose (18F-FDG) in PET/CT imagining in with histiocytosis
EU CTIS ID: 2024-515895-11-00
What this study is testing
Determination of molecular status and benefit and safety of use fludeoxyglucose (18-FDG) in PET/CT imagening in juvenile patients with histiocytosis.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient under 18 years of age at the time of inclusion.
- Histopatologically confirmed or suspected histiocytosis (based on prior test results).
- Signing of informed consent for trial participation according with current legal regulations.
You likely can't join if
- Lack of inclusion criteria.
- Pregnancy.
- Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.